Myriad GeneticsSTU:MYD -1.42%49 Days Payable is 45.20 as of Mar. 2026, which is 6% below its 10-year median of 48.17. GuruFocus rates STU:MYD with a GF Score™ of 49/100 and a GF Value™ of €13.05 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 66.32% on this metric.
The historical rank and industry rank for Myriad Genetics's Days Payable or its related term are showing as below:
STU:MYD'
s Days Payable Range Over the Past 10 Years
Min: 42.04 Med: 48.17 Max: 53.94
Current: 44.97
During the past 13 years, Myriad Genetics's highest Days Payable was 53.94. The lowest was 42.04. And the median was 48.17.
STU:MYD's Days Payable is ranked worse than 66.32% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.385
vs STU:MYD: 44.97
Myriad Genetics's Days Payable
declined
from Mar. 2025 (45.44) to Mar. 2026 (45.20).
It may suggest that Myriad Geneticsaccelerated paying its suppliers.
Myriad Genetics Days Payable Related Terms
Myriad Genetics Days Payable Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Days Payable Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Days Payable distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Myriad Genetics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Days Payable of 45.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Myriad Genetics and its competitors. This is near median its historical median of 48.17. Over the past decade, Myriad Genetics' Days Payable has ranged from 42.04 to 53.94. According to the industry distribution chart, Myriad Genetics ranks #126 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 66.3%.
Is Myriad Genetics' Days Payable too high?
Myriad Genetics' current Days Payable of 45.20 is near median its 10-year median of 48.17. Over the past 10 years, this metric has ranged from a low of 42.04 to a high of 53.94. The Medical Diagnostics & Research industry median Days Payable is 65.39. Myriad Genetics' value of 45.20 is 30.9% below this industry median. Based on the distribution chart, Myriad Genetics ranks #126 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Days Payable compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #126 out of 190 companies for Days Payable. This places Myriad Genetics in the lower half of its industry. The industry median Days Payable is 65.39. Myriad Genetics' value of 45.20 is 30.9% below this benchmark. Historically, Myriad Genetics' own Days Payable has ranged from 42.04 to 53.94 over the past decade. While the company's 10-year median is 48.17 vs. the industry median of 65.39, Myriad Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myriad Genetics's current Days Payable of 45.20 is 30.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Days Payable is 45.20, which is near median its own 10-year median of 48.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.05, compared to a current price of €5.15 — trading 60.5% below its estimated fair value. The current Days Payable is 45.20, which is near median its 10-year median of 48.17 and 30.9% below the Medical Diagnostics & Research industry median of 65.39. Myriad Genetics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Days Payable is 45.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.15 is trading 60.5% below its estimated GF Value™ of €13.05.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Days Payable: 45.20 (near median its 10-year median of 48.17)
GF Value™: €13.05 vs. price of €5.15 (60.5% below fair value)
Industry Position: 30.9% below the Medical Diagnostics & Research median (#126 of 190)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
49GF Score
Get the complete analysis for STU:MYD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
